Pay in 4 interest-free payments of $5.25 Learn more
Ships within 48 hours · Estimated delivery Aug 4 - Aug 9
with an IC50 of 180 nM
The administration of LY-303511
Jończyk J
PF-04494700
MDL-29951 inhibits the human liver (IC50=2
NVP-231 - CAS# 362003-83-6 ticancer activities with an IC50 of 180NVP 231, CAS No. 362003 83 6, is a potent, specific, and reversible CerK inhibitor that competitively inhibits binding of ceramide to CerK. NVP 231 is active in the low nanomolar range on purified as well as cellular CerK and abrogates phosphorylation of ceramide, resulting in decreased endogenous C1P levels. When combined with another ceramide metabolizing inhibitor, such as tamoxifen, NVP 231 synergistically increased ceramide levels and reduced